First-In-Human Study of EOS884448 in Participants With Advanced Cancers.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Intervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers. The study will be conducted in 2 parts. The first part is a dose-escalation to determine the MTD, the RP2D, ...
Multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers. The study will be conducted in 2 parts. The first part is a dose-escalation to determine the MTD, the RP2D, and the safety of EOS884448 in participants with advanced cancers. The subsequent expansion part will further explore safety, PK, PD responses, and antitumor activity of EOS884448 at the RP2D as monotherapy in participants with selected cancer types.
Tracking Information
- NCT #
- NCT04335253
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon